ArticleClinical Medicine Insights. Oncology2012

Emerging Pharmacotherapy for Relapsed or Refractory Hodgkin's Lymphoma: Focus on Brentuximab Vedotin.

Michelle Furtado et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.